Tuesday, August 19, 2014

Hot Heal Care Companies For 2014

California and New York are flush heading into 2014, while at the other extreme Alaska and Kansas are hurting. Overall, most states are in good shape ��albeit with a bit of a hangover from the recession and some uneasiness about the future.

In most states, revenues and expenditures are up, but only 20 have reached their pre-recession peaks when inflation is taken into account. Those shortfalls, and the uncertainty caused by numerous budget showdowns in Congress, have left states unsteady.

"There's more stability and revenues are less volatile," said Scott Pattison, executive director of the National Association of State Budget Officers. "As long as the economy continues to recover, states will continue to have modest growth. I don't expect robust growth. I expect modest growth, until we get the next recession, which hopefully is a ways away."

Top 10 Media Companies To Buy For 2015: Consumer Staples Select Sector SPDR (XLP)

Consumer Staples Select Sector SPDR Fund (the Fund) seeks to provide investment results that correspond to the price and yield performance of the Consumer Staples Select Sector of the S&P 500 Index (the Index). The Index includes companies that are primarily involved in the development and production of consumer products that cover food and drug retailing, beverages, food products, tobacco, household products and personal products.

The Fund utilizes a passive or indexing investment approach to invest in a portfolio of stocks that seek to replicate the Index. The Fund�� investment advisor is SSgA Funds Management, Inc.

Advisors' Opinion:
  • [By Chris Ciovacco]

    The damage from Wednesday's session did little to disturb the market's longer-term risk tolerance profile, which is easy to understand when you consider the S&P 500 is still up 3 points for the week. However, we have seen some emerging cracks over the past two weeks. Demand for bonds has not surpassed stocks, but there is evidence of an attempt to mount a more formidable charge relative to stocks. Recent interest in defensive consumer staples (XLP) also tells us to keep an open mind about a "give back" after the S&P 500 gained 129 points from the October 9 low to the recent high. The observable evidence in the table above aligns with a growth-oriented allocation, including exposure to broad U.S. stock market (VTI), emerging markets (EEM), foreign stocks (EFA), and technology (QQQ).

  • [By Jon C. Ogg]

    4. Cyclical stocks outperform defensive stocks – This puts consumer discretionary, energy, financials, industrials, technology and materials all doing better than consumer staples, healthcare, telecom, and utilities. Doll also prefers a free cash flow yield to dividend yield and dividend growth over dividend yield.

    ETF Recommendation(s): Financial Select Sector SPDR (NYSEArca: XLF), Technology Select Sector SPDR (NYSEArca: XLK), Market Vectors Oil Services ETF (NYSEArca: OIH)… Avoid Consumer Staples Select Sector SPDR (NYSEArca: XLP) and Utilities Select Sector SPDR (NYSEArca: XLU).

    5. Dividends, stock buy-backs, capex, and M&A all increase at a double-digit rate – This is led by a lot of cash flow, underleveraged balance sheets, and possible great places to use cash. The argument for higher cap-ex is as follows: “Pent-up demand and aging of plant, equipment and technology argue for increases in those key areas.”

  • [By Ben Levisohn]

    The exception to the strong defensive performance: consumer staples. The Consumer Staples Select Sector SPDR (XLP) has dropped 2.9% this year, making it the worst-performing sector in the S&P 500. Barclays’ Barry Knappexplains what’s gone wrong:

  • [By Chris Versace, Editor, PowerTrend Brief and PowerTrend Profits]

    That, to me, says they're going to favor inelastic goods over elastic ones, so when you think of the things that we need each and every day, toilet paper, toothpaste, deodorant, shampoo, household cleansers, that sort of thing, that's what brings me into (XLP) and (VDC).

Hot Heal Care Companies For 2014: NET Servicos de Comunicacao S.A.(NETC)

Net Servicos de Comunicacao S.A., through its subsidiaries, provides cable television, Internet access, and voice services in Brazil. It offers cable television services under the ?NET? brand name through various cable networks located in the largest cities of Brazil. The company also offers broadband Internet access services under the ?NET VIRTUA? brand name by using Embratel's IP backbone infrastructure. In addition, it provides voice services under the ?NET FONE VIA EMBRATEL? brand name jointly with Embratel. Further, the company offers integrated video, broadband, and voice services. Net Servicos de Comunicacao S.A. was founded in 1994 and is headquartered in Sao Paulo, Brazil.

Advisors' Opinion:
  • [By Vanina Egea] offers bundled services and has aggressively expanded its Internet and TV subscriber base in the state.

    Investing for Long-term Growth

    Looking forward, Telefè´¸nica Brasil is investing in technology and network expansion to further empower its competitive position. The firm is expanding its 3G network based on CDMA EV-DO and HSPA technologies, which provide a great advantage over its peers. Further, it expects to benefit from the growth opportunities in the 4G market. Consequently, it has signed a deal with Ceragon Networks Ltd. (CRNT) to deploy the superfast 4G network nationwide.

    A Valuable Stock

    Telef贸nica Brasil has a healthy balance sheet with strong cash flow generation (up to 9,576 million in 2013 from 3,488 million in 2011) and reasonable debt levels. Its net debt-to-EBITDA ratio is of 0.17 times and it has a debt- to-equity ratio of 0.2 against its peers��average of 0.9. Its financial strength and a robust dividend have attracted investment gurus like Charles Brandes (Trades, Portfolio) and David Dreman (Trades, Portfolio), who have recently incorporated the company to its portfolio.

    Considering the stock�� trading price of 14.6x its trailing earnings compared to the peer group average of 16.90x, and a compelling dividend yield of 7.30 with a payout ratio of 1.1 (against its competitors��median of 3.53 and 0.62, respectively), I believe this stock is a worthy investment opportunity with excellent growth potential.

    Disclosure: Vanina Egea holds no position in any stocks mentioned.

    Also check out: Charles Brandes Undervalued Stocks Charles Brandes Top Growth Companies Charles Brandes High Yield stocks, and Stocks that Charles Brandes keeps buyingAbout the author:Vanina EgeaA fundamental analyst at Lone Tree Analytics

    Visit Vanina Egea's Website

    Currently 5.00/512345

    Rating: 5.0/5 (1 vote)

    Voters: Subscribe via Email Subscribe RSS Comments Please leave your comment: $(do

Hot Heal Care Companies For 2014: Agenus Inc.(AGEN)

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. It offers Oncophage vaccine for the treatment of adjuvant renal cell carcinoma. The company?s products under development include Prophage series of cancer vaccines, which has been tested in Phase III clinical trials for the treatment of renal cell carcinoma (RCC) and metastatic melanoma, as well as has been tested in Phase I and Phase II clinical trials in various indications; and under Phase II clinical trials in glioma, a type of brain cancer, and adjuvant renal cell carcinoma. The Prophage series of cancer vaccines include R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its product candidate portfolio includes QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer, melanoma, malaria, and shingles, as well as in for the treatment of va rious infectious diseases and Alzheimer?s disease; and HerpV that completed Phase 1 clinical trial for the treatment of genital herpes. The company was formerly known as Antigenics Inc. and changed its name Agenus Inc. in January 2011 to reflect its existing product pipeline. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Advisors' Opinion:
  • [By Lisa Levin]

    Agenus (NASDAQ: AGEN) rose 22.99% to $3.37 after the company reported positive follow-on Phase 2 results for brain cancer vaccine.

    Aeropostale (NYSE: ARO) shares jumped 18.23% to $10.18 after private equity firm Sycamore Partners bought a 7.96% stake in the company.

  • [By Smith On Stocks]

    I am initiating coverage of Agenus (AGEN) with a Buy. I have just published a basic report on my website, which goes into detail on the company's two core technology platforms: (1) the heat shock protein technology that is the basis of therapeutic and preventive vaccines for cancer and infectious disease, and (2) the QS-21 Stimulon adjuvant that is being used by Agenus and other vaccine developers to enhance the effectiveness of their vaccines. This report is a summary of that more detailed report.

  • [By John Udovich]

    Follow-on Stock Offerings From Small Cap Biotech Stocks. Thanks to the boom in biotech IPOs along with the sector�� overall performance, already listed biotechs have the option to ask investors for more cash in the form of a follow-on offering. Recently, FierceBiotech.com noted how four small cap biotechs raised $276 million from follow-on offerings in just one day last week. These small caps�included Epizyme Inc (NASDAQ: EPZM) which raised $88 million, Halozyme Therapeutics, Inc (NASDAQ: HALO) which raised $100 million, Agenus Inc (NASDAQ: AGEN) which raised $52 million and Idera Pharmaceuticals Inc (NASDAQ: IDRA) which raised $36 million. FierceBiotech.com noted that the�steady flow of about $4.5 billion a year in venture cash�along with�more than $3.5 billion from IPOs last year plus all of the�follow-ons are helping to foster both company growth and�accelerate drug�development programs. Mixed Bag for Biotech IPOs. Last Wednesday also saw two small cap biotech IPOs fizzle in one day�with small cap T cell vaccine developer�Genocea Biosciences Inc (NASDAQ: GNCA) raising $60 million but then ending the day down 8.3% to close at $11 while Dutch drug developer uniQure NV (QURE) raised $81.9 million but fell more than 14% to $14.61. However, orphan drug stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX), which is developing�drugs to treat orphan diseases like Tourette syndrome, saw a 30.5% gain to close at $15.66 and raise $84 million. The Boston Globe quoted Michael Ringel, a partner and managing director at Boston Consulting Group who focuses on health care business, as saying:

    ��he mood is incredibly positive. Capital is flowing. [The biotech IPOs]��have been burning hot. I think it�� too early to suggest that is changing. I can�� predict the overall economy any better than anyone else, but I would expect a pretty good year for IPOs.��/p>

Hot Heal Care Companies For 2014: Century Aluminum Company(CENX)

Century Aluminum Company, through its subsidiaries, produces primary aluminum in the United States, China, and Iceland. The company offers high purity primary aluminum, molten aluminum, standard-grade ingots, extrusion billets, and other value-added primary aluminum products. It also holds a 40% joint venture interest in a carbon anode and cathode facility located in the Guangxi Zhuang Autonomous Region of south China. The company was founded in 1981 and is headquartered in Monterey, California.

Advisors' Opinion:
  • [By Rich Smith]

    This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines include upgrades for both Century Aluminum (NASDAQ: CENX  ) and Deutsche Bank (NYSE: DB  ) . But the news isn't all good, so let's start off with a few words on why...

  • [By Jake L'Ecuyer]

    Leading and Lagging Sectors
    Basic materials shares jumped about 1.72 percent in Monday's trading. Leading the sector was strength from Century Aluminum Co (NASDAQ: CENX) and Horsehead Holding (NASDAQ: ZINC). In trading on Monday, utilities shares dropped by 0.13 percent.

  • [By Travis Hoium]

    What: Shares of Century Aluminum (NASDAQ: CENX  ) jumped 13% today after the company announced an acquisition.

    So what: The company is buying the Sebree aluminum smelter for about $61 million in cash from a subsidiary of Rio Tinto Alcan. Century will assume $71 million in working capital and won't be liable for historical environmental liabilities at the plant. �

  • [By Pendulum]

    Amid the challenges in the aluminum industry, Century Aluminum (CENX) has taken positive actions over the last few months. In June, it acquired the Sebree smelter in Kentucky. More importantly, it received approval for a new power contract at its Hawesville facility, which will improve its cost structure, and the company has similar plans for the new Sebree facility. These actions are reducing the company's cost of production and putting it in a better position to manage through the tough part of the aluminum price cycle. As a result of these actions, Century Aluminum's stock price has outperformed its peers. In this article, I will analyze the challenges in the aluminum industry and the positive impact of Century Aluminum's recent actions.

Hot Heal Care Companies For 2014: American Vanguard Corp (AVD)

American Vanguard Corporation, incorporated on January 2, 1969, operates as a holding company. The Company is primarily a chemical manufacturer that develops and markets products for agricultural and commercial uses. The Company manufactures and formulates chemicals for crops, human and animal protection. The Company conducts its business through its subsidiaries, AMVAC Chemical Corporation (AMVAC), GemChem, Inc. (GemChem), 2110 Davie Corporation (DAVIE), Quimica Amvac de Mexico S.A. de C.V. (AMVAC M), AMVAC de Costa Rica Sociedad Anonima (AMVAC CR), AMVAC Switzerland GmbH (AMVAC S), AMVAC do Brasil Representacoes Ltda (AMVAC B), AMVAC Chemical UK Ltd. (AMVAC UK), AMVAC CV (AMVAC CV), AMVAC Netherlands BV (AMVAC BV), and Envance Technologies, LLC (Envance). In July 2012, the Company completed the restructuring of the International Sales & Marketing function of its principal operating subsidiary, AMVAC Chemical Corporation. On November 30, 2012, AMVAC and TyraTech, Inc. formed Envance Technologies, LLC, in which the Company owns 60% of the equity interest. In July 2012, the Company formed AMVAC CV and AMVAC BV.

AMVAC is a chemical manufacturer that develops and markets products for agricultural and commercial uses. It manufactures and formulates chemicals for crops, human and animal health protection. These chemicals, which include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, are marketed in liquid, powder, and granular forms. AMVAC owns and/or operates the Company�� domestic manufacturing facilities and is also the parent company for all its foreign companies. DAVIE owns real estate for corporate use.

GemChem is a national chemical distributor. GemChem, in addition to purchasing key raw materials for the Company, also sells into the pharmaceutical, cosmetic and nutritional markets. GemChem is a wholly owned subsidiary of AVD.

Advisors' Opinion:
  • [By Rich Duprey]

    Just as Monsanto is enjoying a surge in sales of Roundup, pesticide makers are witnessing greater sales of pesticides to combat these superbugs. Revenues at Sygenta (NYSE: SYT  ) rose 1.5% to $4.2 billion, FMC's (NYSE: FMC  ) sales were 5% higher, and American Vanguard's (NYSE: AVD  ) surged 39% last quarter. The three companies account for three-quarters of all ground pesticides sold in the United States.

  • [By Travis Hoium]

    What: Shares of specialty chemical maker American Vanguard (NYSE: AVD  ) jumped 10% today after the company released earnings.

    So what: First-quarter revenue jumped 39% to $121.5 million and adjusted earnings per share nearly doubled to $0.59. Analysts only expected $115.4 million in revenue and earnings of $0.46 per share so the company easily beat on both the top and bottom line. �

  • [By Travis Hoium]

    What: Shares of specialty chemical maker American Vanguard (NYSE: AVD  ) fell 17% today after cautioning about second-quarter earnings.

  • [By Seth Jayson]

    Margins matter. The more American Vanguard (NYSE: AVD  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong American Vanguard's competitive position could be.

Hot Heal Care Companies For 2014: Andatee China Marine Fuel Services Corporation(AMCF)

Andatee China Marine Fuel Services Corporation, through its subsidiaries, engages in the production, storage, distribution, and wholesale purchase, and sale of blended marine fuel oil for cargo and fishing vessels primarily in Tianjin City, and Liaoning, Shandong, and Zhejiang Provinces in the People?s Republic of China. It sells its products through distributors, as well as to retail customers. The company was founded in 1997 and is based in Dalian, the People?s Republic of China.

Advisors' Opinion:
  • [By Roberto Pedone]

    Andatee China Marine Fuel Services (AMCF) is engaged in the production, storage, distribution and wholesale purchases and sales of blended marine fuel oil for cargo and fishing vessels. This stock closed up 4.1% to $1.27 in Thursday's trading session.

    Thursday's Range: $1.22-$1.32

    52-Week Range: $0.45-$2.75

    Thursday's Volume: 150,000

    Three-Month Average Volume: 193,369

    From a technical perspective, AMCF spiked sharply higher here with lighter-than-average volume. This move is quickly pushing shares of AMCF within range of triggering a major breakout trade. That trade will hit if AMCF manages to take out Thursday's high of $1.32 to its 50-day moving average of $1.39 with high volume.

    Traders should now look for long-biased trades in AMCF as long as it's trending above some key near-term support levels at $1.15 or at $1.09 and then once it sustains a move or close above those breakout levels with volume that hits near or above 193,369 shares. If that breakout hits soon, then AMCF will set up to re-test or possibly take out its next major overhead resistance levels at $1.80 to $1.98. Any high-volume move above those levels will then give AMCF a chance to re-test its 52-week high at $2.75.

  • [By Lisa Levin]

    Andatee China Marine Fuel Services (NASDAQ: AMCF) shares touched a new 52-week high of $3.08 on Q2 results.

    CRA International (NASDAQ: CRAI) shares reached a new 52-week high of $26.845. CRA International shares have jumped 45.84% over the past 52 weeks, while the S&P 500 index has gained 18.08% in the same period.

  • [By Roberto Pedone]

    Another under-$10 energy player that's starting to move within range of triggering a big breakout trade is Andatee China Marine Fuel Services (AMCF), which is engaged in the production, storage, distribution and wholesale purchases and sales of blended marine fuel oil for cargo and fishing vessels. This stock has been in play with the bulls so far in 2013, with shares up big by 180%.

    If you take a look at the chart for Andatee China Marine Fuel Services, you'll notice that this stock has been uptrending strong over the last month and change, with shares moving higher from its low of 98 cents per share to its recent high of $1.69 a share. During that move, shares of AMCF have been making mostly higher lows and higher highs, which is bullish technical price action. That move is now starting to push shares of AMCF within range of triggering a big breakout trade above a key downtrend line.

    Market players should now look for long-biased trades in AMCF if it manages to break out above some near-term overhead resistance levels at $1.69 to $1.80 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 215,352 shares. If that breakout hits soon, then AMCF will set up to re-test or possibly take out its next major overhead resistance levels at $1.98 to just above $2.20 a share. Any high-volume move above those levels will then give AMCF a chance to tag its 52-week high at $2.75 a share.

    Traders can look to buy AMCF off any weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support levels at $1.29 or at $1.15 a share. One can also buy AMCF off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By Lisa Levin]

    Andatee China Marine Fuel Services (NASDAQ: AMCF) shares surged 70.29% to $2.98 after the company reported Q2 results.

    Monster Beverage (NASDAQ: MNST) shares climbed 30.97% to $93.84. Coca-Cola Company (NYSE: KO) and Monster Beverage announced a long-term strategic partnership. As part of the deal, Coca-Cola will buy a 16.7% equity stake in Monster.

Hot Heal Care Companies For 2014: Athersys Inc.(ATHX)

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating cardiovascular disease, neurological conditions, inflammatory and immune disorders, and other conditions. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases. The company is also involved in the development of novel small molecule compounds for applications in indications, such as obesity and other areas, including the treatment of neurological conditions, and for the modulation of stem cells or related applications in the regenerative medicine area. It has product co-development collaboration with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease for the worldwide market; Angiotech Pharmaceuticals, Inc. to develop and commerciali ze MultiStem to treat certain cardiovascular diseases, such as acute myocardial infarction; and RTI Biologics, Inc. to develop and commercialize biologic implants for certain orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.

Advisors' Opinion:
  • [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]

    Biotechnology company Athersys Inc.(ATHX) said interim results of a mid-stage study of its MultiStem cell therapy for ulcerative colitis failed to show meaningful benefit in certain cases, though the treatment had favorable safety and tolerability. Shares plunged 52% to $1.30 premarket.

  • [By Lisa Levin]

    Athersys (NASDAQ: ATHX) shares fell 56.04% to reach a new 52-week low of $1.20 on failed trial results for ulcerative colitis.

    Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets

  • [By Roberto Pedone]

    Athersys (ATHX) is a biopharmaceutical company focused in the field of regenerative medicine. This stock closed up 4% to $1.79 in Thursday's trading session.

    Thursday's Range: $1.68-$1.80

    52-Week Range: $0.95-$2.42

    Thursday's Volume: 270,000

    Three-Month Average Volume: 323,188

    From a technical perspective, ATHX bounced notably higher here right off its 50-day moving average of $1.67 with decent upside volume. This stock recently pulled back from $1.99 to its 50-day at $1.67. Shares of ATHX may now be down with that pullback, since the stock is starting to trend higher and move within range of triggering a near-term breakout trade. That trade will hit if ATHX manages to take out some near-term overhead resistance levels at $1.90 to $1.99 with high volume.

    Traders should now look for long-biased trades in ATHX as long as it's trending above its 50-day at $1.67 and then once it sustains a move or close above those breakout levels with volume that hits near or above 323,188 shares. If that breakout triggers soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels at $2.16 to $2.25. Any high-volume move above those levels will put its 52-week high at $2.42 into range for shares of ATHX.

  • [By Sean Williams]

    What: Shares of Athersys (NASDAQ: ATHX  ) , a clinical-stage biotechnology company focused on regenerative medicine, advanced as much as 10% after announcing that it had been granted three new patents for its stem cell and regenerative technologies in Japan.

No comments:

Post a Comment